Back to Search Start Over

Interleukin-5 Supports the Expansion of Fas Ligand-Expressing Killer B Cells that Induce Antigen-Specific Apoptosis of CD4+ T Cells and Secrete Interleukin-10.

Authors :
Klinker, Matthew W.
Reed, Tamra J.
Fox, David A.
Lundy, Steven K.
Source :
PLoS ONE; Aug2013, Vol. 8 Issue 8, p1-13, 13p
Publication Year :
2013

Abstract

Beyond their critical role in humoral immunity, B lymphocytes can employ a variety of immunomodulatory mechanisms including expression of the apoptosis-inducing molecule Fas ligand (FasL; CD178). Here, we extensively characterized the surface phenotype of FasL<superscript>+</superscript> killer B cells, showing they are enriched in the IgM<superscript>high</superscript>CD5<superscript>+</superscript>CD1d<superscript>high</superscript> B cell subset previously reported to contain a higher frequency of B cells producing interleukin-10 (IL-10). A rare population of B cells expressing IL-10 was present among FasL<superscript>+</superscript> B cells, but most FasL<superscript>+</superscript> B cells did not produce IL-10. We also identify interleukin-5 (IL-5) as a novel inducer of killer B cell function. Constitutively FasL<superscript>+</superscript> B cells expressed higher levels of the IL-5 receptor, and treating B cells with IL-5 and CD40L resulted in the expansion of a B cell population enriched for FasL<superscript>+</superscript> cells. B cells stimulated with IL-5 and CD40L were potent inducers of apoptosis in activated primary CD4<superscript>+</superscript> T cells, and this killing function was antigen-specific and dependent upon FasL. IL-5 also enhanced IL-10 secretion in B cells stimulated with CD40L. Taken together these findings elucidate the relationship of FasL<superscript>+</superscript> B cells and IL-10-producing B cells and demonstrate that IL-5 can induce or enhance both killer B cell activity and IL-10 secretion in B cells. Finally, we found that the killer B cell activity induced by IL-5 was completely blocked by IL-4, suggesting the existence of a previously unknown antagonistic relationship between these type-2 cytokines in modulating the activity of killer B cells. Targeting this IL-5/IL-4 signaling axis may therefore represent a novel area of drug discovery in inflammatory disorders. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19326203
Volume :
8
Issue :
8
Database :
Complementary Index
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
90070538
Full Text :
https://doi.org/10.1371/journal.pone.0070131